Abstract
γ-Aminobutyric acid (GABA) activates two qualitatively different inhibitory mechanisms through ionotropic GABAA multisubunit chloride channel receptors and metabotropic GABAB G protein-coupled receptors. Evidence suggests that pharmacologically distinct GABAB receptor subtypes mediate presynaptic inhibition of neurotransmitter release by reducing Ca2+conductance, and postsynaptic inhibition of neuronal excitability by activating inwardly rectifying K+ (Kir) conductance. However, the cloning of GABAB gb1 and gb2 receptor genes and identification of the functional GABAB gb1-gb2 receptor heterodimer have so far failed to substantiate the existence of pharmacologically distinct receptor subtypes. The anticonvulsant, antihyperalgesic, and anxiolytic agent gabapentin (Neurontin) is a 3-alkylated GABA analog with an unknown mechanism of action. Here we report that gabapentin is an agonist at the GABAB gb1a-gb2 heterodimer coupled to Kir 3.1/3.2 inwardly rectifying K+channels in Xenopus laevis oocytes. Gabapentin was practically inactive at the human gb1b-gb2 heterodimer, a novel human gb1c-gb2 heterodimer and did not block GABA agonism at these heterodimer subtypes. Gabapentin was not an agonist at recombinant GABAA receptors as well. In CA1 pyramidal neurons of rat hippocampal slices, gabapentin activated postsynaptic K+currents, probably via the gb1a-gb2 heterodimer coupled to inward rectifiers, but did not presynaptically depress monosynaptic GABAA inhibitory postsynaptic currents. Gabapentin is the first GABAB receptor subtype-selective agonist identified providing proof of pharmacologically and physiologically distinct receptor subtypes. This selective agonism of postsynaptic GABAB receptor subtypes by gabapentin in hippocampal neurons may be its key therapeutic advantage as an anticonvulsant.
Footnotes
- Received March 10, 2000.
- Accepted September 14, 2000.
-
Send reprint requests to: Dr. Gordon Y. K. Ng, Merck Frosst Center for Therapeutic Research, 16711 Trans Canada Hwy., Kirkland, Quebec, Canada (E-mail: gordon_ng{at}merck.com).
-
The work in the laboratory of T.E.H. was supported by the Medical Research Council of Canada, the Heart and Stroke Foundation of Canada, and the Fonds de la Recherche en Santé du Québec (FRSQ). The work in the laboratory of J.-C.L. was supported by the Medical Research Council of Canada, the FRSQ, a Research Center grant from the Fonds pour la Formation de Chercheurs et l'Aide à la Recherche (FCAR) to the Groupe de Recherche sur le Système Nerveux Central (GRSNC), and an Équipe de Recherche grant from the FCAR. S.B. was supported by a postdoctoral fellowship from the GRSNC (FCAR).
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|